AVM Expands Executive Team, Appoints Janet R. Rea COO

Seattle, July 8, 2020 – AVM Biotechnology, a Seattle-based up-and-coming biotech firm whose lead molecule, AVM0703, has received FDA permission to begin clinical trials treating no-option Non-Hodgkin’s Lymphoma, and is applying to begin trials treating moderate-severely ill COVID-19 patients, announced today the hiring of Janet R. Rea, MSPH, as Chief Operating Officer.